¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Benign lipomatous neoplasm of other sites"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® neoplasm ÇÑ±Û ½Å»ý¹°
¼³¸í   
  »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ Çϴ µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼­·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀǠȤ¡±À» ¸»Çϴ °ÍÀ¸·Î ÇǺΰú¿¡¼­´Â À̺¸´Ù ÀÛÀº È¤À» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼­µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀΠ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù.
  
  ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼­ °°Àº º´º¯ÀÌ ¹ß»ýÇϴ ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾ´Ù. µû¶ó¼­ »ý¸íÀ» ´ÜÃà½Ã۴ °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù.
¿µ¹® benign ÇÑ±Û ¾ç¼º
¼³¸í   
  Ä¡À¯°¡ Àß µÇ´Â, Á¾¾çÀÇ °æ¿ì¿¡¼­´Â ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾Ê°í ±×ºÎºÐ¿¡¼­ ¸Ó¹°·¯ Àִ Á¾¾çÀ» ¸»ÇÑ´Ù.
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
¿µ¹® Benign Prostatic Hyperplasia(BPH) ÇÑ±Û Àü¸³»ùºñ´ë
¼³¸í   
  50¼¼ ÀÌ»óÀÇ ³²¼º¿¡ ºó¹ßÇϴ º´À¸·Î Àü¸³»ùÀÇ ¿äµµ ÁÖÀ§ ¿µ¿ª¿¡ Å«°áÀýÀ» Çü¼ºÇÏ¿©, À̰ÍÀÌ Ä¿Áö¸é ¿äµµ¸¦ ¾Ð¹ÚÇÏ¿© ºÎºÐÀû È¤Àº ¿ÏÀüÇÑ ¿äµµÆó»öÀ» ÀÏÀ¸Å°´Â º´ÀÌ´Ù. Áõ»óÀº ¿äµµÆó»ö¿¡ µû¸¥ ¼Òº¯ÀÇ °¨¼Ò¿Í ¹æ±¤ÀÚ±ØÁõ»óÀ¸·Î ºó´¢, ÀÜ´¢°¨, ¼Òº¯À» ÂüÀ» ¼ö ¾ø´Â Áõ»ó µîÀÌ´Ù. Ä¡·á´Â °æ¿äµµ Àü¸³»ù ÀûÃâ¼ú·Î Àü¸³¼±ÀÇ ºñ´ëÇÑ ºÎºÐÀ» ÀýÁ¦ÇؾߠÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • benign neoplasm
    ¾ç¼ºÁ¾¾ç
  • lipomatous polyp
    Áö¹æÁ¾Æú¸³
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cystic neoplasm
    ³¶¼º½Å»ý¹°, ³¶¼ºÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • benign
    ¾ç¼º-
  • benign cyst
    1. ¾ç¼º³¶, ¾ç¼º¹°È¤ 2. ¾ç¼º³¶Á¾
  • benign juvenile melanoma
    ¾ç¼º¼Ò¾ÆÈæ»öÁ¾
  • benign lichenoid keratosis
    ¾ç¼ºÅ¼±°¢È­Áõ
  • benign lymphoid hyperplasia
    ¾ç¼º¸²ÇÁ°ú´ÙÇü¼º
  • benign masseteric hypertrophy
    ¾ç¼º±ú¹°±Ùºñ´ë, ¾ç¼º±³±Ùºñ´ë
  • benign migratory glossitis
    ¾ç¼ºÀÌÁÖÇô¿°, ¾ç¼ºÀÌÁÖ¼³¿°
  • benign papular acantholytic dermatosis
    ¾ç¼º±¸Áø°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • benign prostatic hypertrophy
    ¾ç¼ºÀü¸³»ùºñ´ë, ¾ç¼ºÀü¸³¼±ºñ´ë
  • benign tumor
    ¾ç¼ºÁ¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • cystic neoplasm
    ³¶Á¾
  • benign cyst
    1.¾ç¼º³¶, ¾ç¼º¹°È¤, 2.¾ç¼º³¶Á¾
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • benign cystic teratoma
    ¾ç¼º³¶±âÇüÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipomatous polyp
    Áö¹æÁ¾¼ºÆú¸³
  • borderline malignant epithelial ovarian neoplasm
    °æ°è¾Ç¼º»óÇdz­¼ÒÁ¾¾ç
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • benign
    ¾ç¼º-
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • benign cystic teratoma
    ¾ç¼º³¶±âÇüÁ¾
  • benign juvenile melanoma
    ¾ç¼º¿¬¼ÒÈæ»öÁ¾
  • benign lichenoid keratosis
    ¾ç¼ºÅ¼±¾ç°¢È­Áõ
  • benign lymphoid hyperplasia
    ¾ç¼º¸²ÇÁ°ú´ÙÇü¼º
  • benign masseteric hypertrophy
    ¾ç¼º±ú¹°±Ùºñ´ë
  • benign migratory glossitis
    ¾ç¼ºÀÌÁÖÇô¿°
  • benign papular acantholytic dermatosis
    ¾ç¼º±¸Áø°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • benign prostatic hypertrophy
    ¾ç¼ºÀü¸³»ùºñ´ë
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¾ç¼º»óÇdz»ÀÌ»ó°¢È­Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • Hailey-Hailey disease = familial benign chronic pemphigus
    ÇìÀϸ®-ÇìÀϸ®º´
  • hereditary benign intraepithelial dyskeratosis
    À¯Àü¼º ¾ç¼º »óÇdz» ÀÌ»ó°¢È­Áõ
  • hypertension,benign nephrosclerosis
    ¾ç¼º ½Å°æÈ­Áõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • lipomatous polyp
    Áö¹æÁ¾¼º Æú¸³.
  • lipomatous pseudohypertrophy
    Áö¹æ Á¾¼º °¡ºñ´ë(¡­Ê£ÝþÓÞ).
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË).
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË)
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • lymphoplasmacytic neoplasm
    ¸²ÇÁÇüÁú¼¼Æ÷¼º ½Å»ý¹°
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª).
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª)
  • neoplasm =neoplasma
    ½Å»ý¹° Á¾¾ç(¡­ðþåË)
  • organoid neoplasm
    ±â°ü¾ç½Å»ý¹°(ÐïίåÆãæßæÚª)
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª).
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª)
  • thyroid neoplasm
    °©»ó¼±½Å»ý¹°(¡­ãæßæÚª)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half-of-the-sites reactivity
    ¹Ý(Úâ)ÀÚ¸® ¹ÝÀÀ¼º (Úãëëàõ)
  • splice sites
    ½ºÇöóÀ̽º ÀÚ¸®
  • switching sites
    ¾ù¹Ù²ñ ÀÚ¸®
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°
  • neoplasm
    ½Å»ý¹°
  • benign
    ¾ç¼º
  • benign prostatic hypertrophy
    ¾ç¼ºÀü¸³¼±ºñ´ë(Áõ)
  • benign tumor
    ¾ç¼ºÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
KLS kidneys, liver, and spleen; Kreuzbein lipomatous syndrome
CBN cannabinol; central benign neoplasm; Commission on Biological Nomenclature
PBN paralytic brachial neuritis; peripheral benign neoplasm; polymyxin B sulfate, bacitracin, and neomyc...
BPV benign paroxysmal vertigo; benign positional vertigo; bioprosthetic valve; bovine papilloma virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SMN Second Malignant Neoplasm
DRO Differential Reinforcement of Other Behaviour
MOTT Mycobacteria Other Than Tuberculosis
OND Other Neurological Diseases
SO significant other
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • D17.7
    Benign lipomatous neoplasm of other sites
    ±âŸ ºÎÀ§ÀÇ ¾ç¼º Áö¹æÁ¾¼º ½Å»ý¹°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • disseminated malignant neoplasm
    ÆÛÁ® ÀÖ´Â ¾Ï
  • hematologic neoplasm
    Ç÷¾× ½Å»ý¹°
  • immunologic neoplasm
    ¸é¿ªÇÐÀû ½Å»ý¹°, ¸é¿ªÇÐÀû Á¾¾ç
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
  • benign aphthae
    ¾ç¼º ¾ÆÇÁŸ
  • benign cementoblastoma
    ¾ç¼º ¹é¾Ç¸ð¼¼Æ÷Á¾, ¾ç¼º ¹é¾Ç¾Æ¼¼Æ÷Á¾
    1. ¸ðµç ¿¬·É¿¡¼­ »ó, ÇÏ, ÁÂ¿ì ¾çÃø¿¡¼­ µ¿½Ã¿¡ ¹ß»ý. Ä¡±Ù ÁÖÀ§¿¡ ¹é¾ÇÁúÀ̳ª ¹é¾ÇÁú¾ç Á¶Á÷ÀÇ µ¢¾î¸®¸¦ Çü¼ºÇÏ´Â ±â´ÉÀû Á¶¹é¾Ç¼¼Æ÷·Î ÀÌ·ç¾îÁø ¾ç¼º Á¾¾çÀÌ´Ù.
  • benign chondroblastoma
    ¾ç¼º ¿¬°ñ¾Æ¼¼Æ÷Á¾
    ¿¬°ñ¾Æ¼¼Æ÷ ¶Ç´Â ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýµÇ¾î ¿¬°ñ¼¼Æ÷·Î ºÐÈ­µÇ´Â °æÇâÀ» °®´Â ¼¼Æ÷·Î ±¸¼ºµÈ ¾ç¼º Á¾¾çÀÌ´Ù.
  • benign cystic teratoma
    ¾ç¼º ±âÇüÁ¾
  • benign familial pemphigus
    ¾ç¼º °¡Á·¼º õÆ÷â
    µå¹°°Ô ¹ß»ýÇÏ´Â, À¯Àü¼ºÀ̸ç Áö¼ÓÀûÀ¸·Î Àç¹ßÀ» ¹Ýº¹ÇÏ´Â ¼ÒÆ÷¼º ¹× ÀÛÀº ¼öÆ÷¼º ÇǺο°À¸·Î, ¾×¿Í, ¼­ÇýºÎ ¹× ¸ñ ºÎÀ§¸¦ °¡Àå Àß Ä§¹üÇÏÁö¸¸, ¶§·Î´Â ±¤¹üÇÑ ºÎÀ§¸¦ ħ¹üÇÑ´Ù. º´º¯Àº ´Ù¹ß¼ºÀ̸ç, ¼öÁÖÀÏ ³»Áö ¼ö°³¿ù ÈÄ¿¡ ¼èÅðÇÑ´Ù. ÀÌ ÁúȯÀº »ó¿°»öü ¿ì¼º À¯ÀüÀ» ÇÑ´Ù.
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
lipomatous Pertaining to or manifesting the features of lipoma, or characterised by the presence of a lipoma (or lipomas).
(05 Mar 2000)
lipomatous hypertrophy Nonencapsulated adipose tissue forming a lipoma-like mass, usually in the cardiac interatrial septum where it may cause arrhythmia and sudden death.
Synonym: lipomatous hypertrophy.
(05 Mar 2000)
lipomatous infiltration Nonencapsulated adipose tissue forming a lipoma-like mass, usually in the cardiac interatrial septum where it may cause arrhythmia and sudden death.
Synonym: lipomatous hypertrophy.
(05 Mar 2000)
lipomatous polyp A polyp consisting chiefly of adipose tissue, lipoma that bulges from the surface or is attached by means of a stalk.
(05 Mar 2000)
attachment sites <microbiology, molecular biology> Particular loci in both bacterial and phage DNA molecules at which phage DNA is integrated into the bacterial DNA by recombination between these sites.
(12 Dec 1998)
binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
(12 Dec 1998)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
chromosome fragile sites Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations, and, when located on sex chromosomes, they produce phenotypic abnormalities. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus.
(12 Dec 1998)
contact sites A Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
contact sites B Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
crohn disease: sites <radiology> Oesophagus: rare, stomach (2-20%): granulomatous gastritis, pseudo-post Bilroth-I appearance, ramshorn sign, antral-duodenal fistula, duodenum (4-10%): almost always associated with gastric involvement, bulb and proximal half of duodenum, small bowel (80%): regional enteritis, terminal ileum (alone/in combination): 95%, jejunum/ileum: 15%, commonly associated with medial caecal defect, colon (22-55%): granulomatous colitis, particularly on the right side, transverse stripe sign: contrast within coarse mucosal folds, rectum (35-50%) see: Crohn disease
(12 Dec 1998)
sequence tagged sites Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database.
(12 Dec 1998)
sequence-tagged sites Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasm
    (º´¸®)ü³»¿¡ »ý±â´Â ½Å»ý¹°;(ƯÈ÷)Á¾¾ç
  • benign
    Àھַοî; ÀÎÀÚÇÑ; Ä£ÀýÇÑ
  • benign
    ÀÎÁ¤¸¹Àº;Ä£ÀýÇÑ;¿ÂÈ­ÇÑ;¾ç¼­ÀÇ
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á